Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Net Income (2016 - 2025)

Historic Net Income for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to -$3.0 million.

  • Standard Biotools' Net Income rose 4016.74% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.9 million, marking a year-over-year decrease of 5497.26%. This contributed to the annual value of -$138.9 million for FY2024, which is 8573.97% down from last year.
  • According to the latest figures from Q3 2025, Standard Biotools' Net Income is -$3.0 million, which was up 4016.74% from -$15.8 million recorded in Q2 2025.
  • In the past 5 years, Standard Biotools' Net Income ranged from a high of -$3.0 million in Q3 2025 and a low of -$76.3 million during Q1 2022
  • Its 5-year average for Net Income is -$26.4 million, with a median of -$19.9 million in 2023.
  • Its Net Income has fluctuated over the past 5 years, first crashed by 30582.16% in 2022, then soared by 7786.58% in 2023.
  • Standard Biotools' Net Income (Quarter) stood at -$9.4 million in 2021, then tumbled by 121.07% to -$20.8 million in 2022, then rose by 4.56% to -$19.9 million in 2023, then crashed by 277.45% to -$75.1 million in 2024, then skyrocketed by 96.0% to -$3.0 million in 2025.
  • Its Net Income stands at -$3.0 million for Q3 2025, versus -$15.8 million for Q2 2025 and -$26.0 million for Q1 2025.